Skip to main content
OpenTrials
Completed

NCT Number: NCT01104740

Dengue Seroprevalence Study in Blood Donors in the French West Indies

Dengue is an infectious disease most prevalent in the world. This disease is endemic in the Caribbean, with an increase in seasonal rains. Several outbreaks have been observed in recent years, in 2001, 2005 and 2007, during which further particularly virulent serotypes have emerged. The clinical expression of dengue fever is variable, ranging from no symptoms to a classical form with fever, and even of severe or lethal bleeding. With the possible existence of silent forms of the disease, there are no data identifying the current level of protection of the population in Martinique / Guadeloupe.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Blood Donors Arbovirus Infections Dengue Flaviviridae Infections Flavivirus Infections Hemorrhagic Fevers, Viral Infections Mosquito-Borne Diseases RNA Virus Infections Vector Borne Diseases Virus Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

French Blood Establishment of Guadeloupe, Pointe-à-Pitre, Guadeloupe

Loading trial locations.

About this study

  • Principal objective:

To estimate the prevalence of the specific antibodies of the dengue (IgG) in blood donors in the French West Indies.

  • Secondary objective:

To specify the serotypic specificity of the anti-dengue antibodies detected during the study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Eligible for blood donation following the French legislation,
  • Resident in Martinique /Guadeloupe for at least one year
  • Consent signed

Exclusion criteria

  • Not Eligible for blood donation following the French legislation,
  • Not Resident in Martinique / Guadeloupe for at least one year
  • Consent not signed

Treatment and study plan

Biological sample collection

Other

Blood (serum) sample collection

Primary outcomes

  1. Presence or not of dengue virus-specific immunoglobulin G antibodies

    Time frame: 1 day

Secondary outcomes

  1. Characterization of dengue virus serotype-specific IgG

    Time frame: 1 day

    Characterization of dengue virus serotype-psecific IgG whendengue virus serotype-specific immunoglobulin G antibodies Test is positive

Sponsors and collaborators

Lead sponsor

Etablissement Français du Sang, Martinique

Other

Collaborators

  • Clinique Antilles-Guyane
  • Institut National de la Santé Et de la Recherche Médicale, France
  • Sanofi Pasteur, a Sanofi Company

Registry information

Acronym: DengSeroprevAn

Important dates

Study start
2011
Primary completion
2011
Study completion
2012
First posted
Apr 15, 2010
Registry last updated
Aug 20, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.